Astellas Pharma Inc
F:YPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Astellas Pharma Inc
F:YPH
|
JP |
|
A
|
American Water Works Company Inc
XMUN:AWC
|
US |
|
China Conch Venture Holdings Ltd
F:68C
|
CN |
|
Banco Bilbao Vizcaya Argentaria SA
MAD:BBVA
|
ES |
|
Z
|
Zhong An Group Ltd
F:35Z
|
CN |
|
Wharf Real Estate Investment Company Ltd
OTC:WHREY
|
HK |
|
H
|
Heartland Group Holdings Ltd
F:73X
|
NZ |
|
S
|
Skyworks Solutions Inc
F:AWM
|
US |
|
B
|
Boozt AB
SWB:BOK
|
SE |
|
AxoGen Inc
F:LT3
|
US |
|
Marley Spoon Group SE
OTC:FSESF
|
LU |
|
UniCredit SpA
F:CRIP
|
IT |
|
L
|
LSI Industries Inc
SWB:LS2
|
US |
|
Megawatt Lithium and Battery Metals Corp
F:WR20
|
CA |
|
N
|
NOVONIX Ltd
SWB:GC3
|
AU |
|
Compania de Minas Buenaventura SAA
F:MBU
|
PE |
|
Co-Diagnostics Inc
NASDAQ:CODX
|
US |
|
G
|
Givaudan SA
F:GIN
|
CH |
|
MEITEC Group Holdings Inc
OTC:MEITF
|
JP |
|
A
|
American Coastal Insurance Corp
F:0UI
|
US |
|
COMSovereign Holding Corp
OTC:COMS
|
US |
|
White Cliff Minerals Ltd
OTC:WCMLD
|
AU |
|
L
|
Logitech international SA
DUS:LTEC
|
CH |
|
P
|
PPG Industries Inc
DUS:PPQ
|
US |
Intrinsic Value
Is YPH undervalued or overvalued?
See the intrinsic value estimate for 
Astellas Pharma Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Astellas Pharma Does
Astellas Pharma is a Japanese drug company that discovers, develops, makes, and sells prescription medicines. Its main products treat areas such as urology, transplant medicine, immunology, cancer, and eye disease. The company spends heavily on research and then brings branded drugs through testing, approval, manufacturing, and distribution.
- Headquarters
- Japan JP
- Employees
- 13 643
- IPO date
- May 16, 1949
Astellas Pharma has no economic moat
Patent protection keeps copies of individual Astellas medicines out temporarily, but does not provide lasting protection across the business. Generic competition has reduced Myrbetriq sales, while competing treatments give doctors alternatives to medicines such as Xtandi.
Read the full moat analysis
Revenue & Expenses Breakdown
Astellas Pharma Inc
Earnings Waterfall
Astellas Pharma Inc
The intrinsic value for Astellas Pharma Inc (YPH) under the Base Case is hidden EUR.
Compared with the current market price of 14.3 EUR, the stock appears hidden.
